B
Bullisch
Bullisch · 25%EXOZ
$12.90
Szenariopreis
$4.400
+0.311 (+7.06%)Zum Schluss
Loading chart…
- Hoch
- 4.585
- Eröffnung
- 4.190
- Volumengewichteter Durchschnittskurs
- 4.37
- Volumen
- 10.79K
- Marktkap.
- —
- Tief
- 4.110
- Umsatz
- 47.09K
- EV/EBITDA, TTM
- 0.00
eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells.
KI-Analyse of eXoZymes Inc (EXOZ)
KaufenExozymes Inc. is a good buy right now due to its recent positive momentum and funding support. The current price is $4.52, and the stock has seen a 5-day change of +20.53%, indicating strong short-term performance. Additionally, the company secured a $2.02 million NIH grant, which enhances its financial backing and growth potential. However, the main risk is the negative earnings trend, with a projected EPS of -0.33 for the last quarter, reflecting ongoing losses.
Bewertungskennzahlen
Das aktuelle erwartete KGV von eXoZymes Inc (EXOZ) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von 0.00.
Alphio-AI-Kursszenarien für EXOZ
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
8.506-24seekingalphaeXoZymes Secures $2.02M NIH Grant for Cannabinoid Research
- 8.506-08seekingalpha
eXoZymes Prices Public Offering to Raise $5.33 Million
9.504-07Yahoo FinanceMDB Capital Holdings Earnings Outlook
9.504-01Yahoo FinanceEXoZymes Inc Earnings Report Analysis and Outlook
- 9.503-31seekingalpha
eXoZymes Reports Increased FY Net Loss and Rising Expenses
EXOZ FAQ – beantwortet von Alphio AI
eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells. It operates in the Healthcare sector.
Exozymes Inc. is a good buy right now due to its recent positive momentum and funding support. The current price is $4.52, and the stock has seen a 5-day change of +20.53%, indicating strong short-term performance. Additionally, the company secured a $2.02 million NIH grant, which enhances its financial backing and growth potential. However, the main risk is the negative earnings trend, with a projected EPS of -0.33 for the last quarter, reflecting ongoing losses.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.